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Purpose of the study
To compare changes in total limb fat by DEXA scan assess-
ment after switching from an AZT/3TC backbone to TVD
vs. maintaining an AZT/3TC regimen.
Methods
72 weeks, open label, randomised, controlled study. Viro-
logically-suppressed HIV-infected patients (<50 c/mL) on
HAART containing AZT/3TC (plus either an NNRTI or a
PI) were assigned to either switch their AZT/3TC back-
bone to TVD or continue current AZT/3TC-containing reg-
imen. Stratification was performed by third agent of
HAART (either NNRTI or PI).
Summary of results
80 patients included (39 TVD; 41 AZT/3TC). Mean age
was 44 years. Patients were predominantly male (81%).
The median CD4 cell count at baseline was higher in the
TVD vs AZT/3TC arm (655 vs. 504 cel/mm3; p = 0.037).
(Tables 1 and 2.)
Five patients discontinued due to an adverse event before
week 24; one in the TVD group (upper abdominal pain)
and four in AZT/3TC group (two renal cholic, one anae-
mia, one lactic acidosis). Changes from BL in GFR (CG)
were -11.8 for TVD and -3.6 mL/min for AZT/3TC.
Conclusion
Through 48 weeks, switching from a suppressive HAART
regimen containing AZT/3TC to TVD, was well tolerated,
maintained efficacy and led to a significant improvement
in limb fat content. Additionally, haemoglobin and
hematocrit significantly improved for patients switched
from AZT/3TC to TVD.
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Table 1: Efficacy outcomes at Week 48.
TVD AZT/3TC p-value
% of Pts with HIV RNA < 50 c/mL (M = F) 92% 78% 0.12
Median CD4 count change (cell/mm3) +60.5 +9 0.079
M = F denotes missing = failure analysis.
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Table 2: Week 48 median changes from BL in limb fat, haematology and lipids
TVD arm (BL) TVD arm (Week 48 – BL) AZT/3TC arm (BL) AZT/3TC arm (Week 48 – BL) p-value
Total limb fat (g) 3565 +392 3946 -257 0.001
Hb (g/dL) 14.6 +0.9 14.9 +0.3 0.007
Hematocrit (%) 42.6 +2.7 42.0 +1.0 0.001
Total Cholesterol (mg/dL) 187.0 +4.5 189.0 +1.0 0.97
LDL-c (mg/dL) 109.0 +7.0 107.5 +5.0 0.66
HDL-c (mg/dL) 49.0 -2.0 49.5 +2.0 0.29
TG (mg/dL) 110.0 +1.5 120.0 +4.0 0.96
BL = baseline.
